Allos Therapeutics to Present at the Needham & Company Biotechnology Conference

Allos Therapeutics to Present at the Needham & Company
Biotechnology Conference 


WESTMINSTER, Colo., May 19  /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc.
(NASDAQ:ALTH) today announced that the Company will participate in Needham &
Company's 2005 Biotechnology Conference, to be held May 25 - 26 in New York
City.  Michael E. Hart, the Company's President and Chief Executive Officer,
will give a 30-minute corporate overview on Thursday, May 26 at 11:00 AM ET.

The presentation will be webcast live and may be accessed by visiting the Allos
website at http://www.allos.com/.  A replay of the webcast will also be
available on the company's website until Friday, June 10, 2005.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. (NASDAQ:ALTH) is a biopharmaceutical company focused
on developing and commercializing innovative small molecule therapeutics for
the treatment of cancer.  Our lead product candidate, EFAPROXYN(TM)
(efaproxiral), is a synthetic small molecule designed to sensitize hypoxic, or
oxygen-deprived, tumor tissue during radiation therapy. EFAPROXYN is currently
being evaluated as an adjunct to whole brain radiation therapy in a pivotal
Phase 3 trial in women with brain metastases originating from breast cancer. 
Our other product candidates are: PDX (pralatrexate), a small molecule
chemotherapeutic agent (DHFR inhibitor) currently under investigation as both a
single agent and in combination therapy regimens in patients with non-small
cell lung cancer and Non-Hodgkin's lymphoma; and RH1, a small molecule
chemotherapeutic agent bioactivated by the enzyme DT-diaphorase currently under
evaluation in patients with advanced solid tumors.  For more information,
please visit the company's web site at: http://www.allos.com/.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties, including those to be discussed in
the presentation and others that can be found in the "Risk Factors" section of
the Company's Form 10-K/A for the year ended December 31, 2004 and in the
Company's periodic reports on Form 10-Q and Form 8-K.  The Company does not
undertake any obligation to update any forward-looking statements contained in
the anticipated presentation as a result of new information, future events or
otherwise.  The Company cautions investors not to place undue reliance on the
forward-looking statements contained in the presentation.  No forward-looking
statement can be guaranteed and actual events and results may differ materially
from those projected. 

DATASOURCE: Allos Therapeutics, Inc.



CONTACT:  Jennifer Neiman, Manager, Corporate Communications of Allos

Therapeutics, [phone], 



Web site:  http://www.allos.com/ 

Copyright